HealVax

HealVax is a private Swiss biotech company developing therapeutic vaccines for chronic inflammatory skin disease and related immune-mediated disorders. The company’s lead program is a psoriasis vaccine designed to induce active immunization against interleukin-17, a clinically validated cytokine target in dermatology. HealVax’s platform uses engineered plant virus-derived virus-like particles with an incorporated tetanus-toxoid T cell epitope to enhance immune responses. The company has described additional interest in atopic dermatitis and multiple sclerosis, and has operated with a lean, virtual model supported by academic and biotech collaborations.